Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution

References

• Alfaro JF, Jones JP. (2008). Studies on the mechanism of aldehyde oxidase and xanthine oxidase. J Org Chem 73:9469–72
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Lanigan RM, Ruda GF, et al. (2016). 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors. J Med Chem 59:1388–409
   PubMed Web of Science ®Google Scholar
• Berry WL, Janknecht R. (2013). KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73:2936–42
   PubMed Web of Science ®Google Scholar
• Blair LP, Cao J, Zou MR, et al. (2011). Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer. Cancers 3:1383–404
   PubMedGoogle Scholar
• Carpani G, Racchi M, Ghezzi P, et al. (1990). Purification and characterisation of mouse liver xanthine oxidase. Arch Biochem Biophys 279:237–41
   PubMed Web of Science ®Google Scholar
• Coelho C, Foti A, Hartmann T, et al. (2015). Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase. Nat Chem Biol 11:779–83
   PubMed Web of Science ®Google Scholar
• Coelho C, Mahro M, Trincao J, et al. (2012). The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem 287:40690–702
   PubMed Web of Science ®Google Scholar
• Dalgaard L. (2015). Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharm Toxicol Methods 74:80–92
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zientek M. (2015). Metabolism of xenobiotics by aldehyde oxidase. Curr Protoc Toxicol 63:4.41.1–13
   Google Scholar
• Falciani F, Terao M, Goldwurm S, et al. (1994). Molybdenum(VI) salts convert the xanthine oxidoreductase apoprotein into the active enzyme in mouse L929 fibroblastic cells. Biochem J 298:69–77
   PubMed Web of Science ®Google Scholar
• Garattini E, Fratelli M, Terao M. (2008). Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019–48
   PubMed Web of Science ®Google Scholar
• Helin K, Dhanak D. (2013). Chromatin proteins and modifications as drug targets. Nature 502:480–8
   PubMed Web of Science ®Google Scholar
• Hoffmann I, Roatsch M, Schmitt ML, et al. (2012). The role of histone demethylases in cancer therapy. Mol Oncol 6:683–703
   PubMed Web of Science ®Google Scholar
• Kawazu M, Saso K, Tong KI, et al. (2011). Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PloS One 6:e17830
   PubMed Web of Science ®Google Scholar
• Kooistra SM, Helin K. (2012). Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13:297–311
   PubMed Web of Science ®Google Scholar
• Li W, Zhao L, Zang W, et al. (2011). Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem Biophys Res Commun 416:372–8
   PubMed Web of Science ®Google Scholar
• Liu G, Bollig-Fischer A, Kreike B, et al. (2009). Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28:4491–500
   PubMed Web of Science ®Google Scholar
• Lohse B, Kristensen JL, Kristensen LH, et al. (2011). Inhibitors of histone demethylases. Bioorg Med Chem 19:3625–36
   PubMed Web of Science ®Google Scholar
• Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–60
   PubMed Web of Science ®Google Scholar
• Roberts J, Wilso I, Henley AT, et al. (2016). Capillary microsampling of mouse blood in early pre-clinical studies: a preferred alternative to dried blood spot sampling. J Bioanal Biomed [Epub ahead of print]. doi:10.4172/1948-593X.1000149
   Google Scholar
• Roesch A, Vultur A, Bogeski I, et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23:811–25
   PubMed Web of Science ®Google Scholar
• Sanoh S, Tayama Y, Sugihara K, et al. (2015). Significance of aldehyde oxidase during drug development: effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52–63
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69–80
   PubMed Web of Science ®Google Scholar
• Shiau C, Trnka MJ, Bozicevic A, et al. (2013). Reconstitution of nucleosome demethylation and catalytic properties of a Jumonji histone demethylase. Chem Biol 20:494–9
   PubMedGoogle Scholar
• Terao M, Romao MJ, Leimkuhler S, et al. (2016). Structure and function of mammalian aldehyde oxidases. Arch Toxicol 90:753–80
   PubMed Web of Science ®Google Scholar
• Walters ZS, Villarejo-Balcells B, Olmos D, et al. (2014). JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 33:1148–57
   PubMed Web of Science ®Google Scholar
• Westaway SM, Preston AG, Barker MD, et al. (2016). Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one derivatives. J Med Chem 59:1370–87
   PubMed Web of Science ®Google Scholar
• Workman P, Aboagye EO, Balkwill F, et al. (2010). Guidelinefor the welfare and use of animals in cancer research. Br J Cancer 102:1555–77
   PubMed Web of Science ®Google Scholar
• Yang J, AlTahan AM, Hu D, et al. (2015). The role of histone demethylase KDM4B in Myc signalling in neuroblastoma. J Natl Cancer Inst 107:djv080
   PubMedGoogle Scholar
• Young LC, Hendzel MJ. (2013). The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochem Cell Biol 91:369–77
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu HH, Weller P, et al. (2011). In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolises a p38 kinase inhibitor. Pharm J 11:15–24
   Google Scholar